Regeneron Pharmaceuticals (REGN) Competitors $673.60 -0.67 (-0.10%) Closing price 02/14/2025 04:00 PM EasternExtended Trading$673.50 -0.10 (-0.01%) As of 02/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends REGN vs. AMGN, VRTX, GILD, ALNY, BIIB, UTHR, INCY, BMRN, NBIX, and EXELShould you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry. Regeneron Pharmaceuticals vs. Amgen Vertex Pharmaceuticals Gilead Sciences Alnylam Pharmaceuticals Biogen United Therapeutics Incyte BioMarin Pharmaceutical Neurocrine Biosciences Exelixis Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability, community ranking and analyst recommendations. Which has more risk and volatility, AMGN or REGN? Amgen has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500. Do analysts rate AMGN or REGN? Amgen currently has a consensus target price of $314.09, indicating a potential upside of 7.88%. Regeneron Pharmaceuticals has a consensus target price of $973.13, indicating a potential upside of 44.47%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 10 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.46Regeneron Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 2.76 Which has stronger earnings and valuation, AMGN or REGN? Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$33.42B4.68$6.72B$7.5538.56Regeneron Pharmaceuticals$14.20B5.21$3.95B$38.2817.60 Do insiders and institutionals hold more shares of AMGN or REGN? 76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.7% of Amgen shares are owned by insiders. Comparatively, 7.5% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor AMGN or REGN? Amgen received 2 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 72.03% of users gave Amgen an outperform vote while only 66.93% of users gave Regeneron Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmgenOutperform Votes155072.03% Underperform Votes60227.97% Regeneron PharmaceuticalsOutperform Votes154866.93% Underperform Votes76533.07% Does the media refer more to AMGN or REGN? In the previous week, Amgen had 1 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 58 mentions for Amgen and 57 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 1.11 beat Regeneron Pharmaceuticals' score of 0.36 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 43 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 23 Very Positive mention(s) 2 Positive mention(s) 26 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is AMGN or REGN more profitable? Regeneron Pharmaceuticals has a net margin of 31.07% compared to Amgen's net margin of 12.24%. Amgen's return on equity of 176.32% beat Regeneron Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amgen12.24% 176.32% 11.71% Regeneron Pharmaceuticals 31.07%16.32%12.76% SummaryRegeneron Pharmaceuticals beats Amgen on 10 of the 19 factors compared between the two stocks. Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REGN vs. The Competition Export to ExcelMetricRegeneron PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$79.35B$6.98B$5.84B$9.14BDividend YieldN/A2.90%5.27%4.00%P/E Ratio17.609.6826.2019.39Price / Sales5.21297.61468.35124.16Price / Cash15.8875.4646.1438.90Price / Book2.525.527.275.05Net Income$3.95B$123.25M$3.19B$222.74M7 Day Performance-5.13%2.85%2.82%2.11%1 Month Performance-4.24%2.19%4.59%2.33%1 Year Performance-29.45%1.61%22.54%16.79% Regeneron Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REGNRegeneron Pharmaceuticals4.8685 of 5 stars$673.60-0.1%$973.13+44.5%-28.9%$79.35B$14.20B17.6013,450Dividend AnnouncementAMGNAmgen4.4913 of 5 stars$293.87+0.1%$314.09+6.9%+0.4%$157.93B$33.42B38.9226,700Insider TradeShort Interest ↑Positive NewsVRTXVertex Pharmaceuticals4.3265 of 5 stars$468.13-0.3%$502.58+7.4%+9.8%$120.56B$9.87B-235.245,400Earnings ReportAnalyst ForecastInsider TradeAnalyst RevisionNews CoverageGILDGilead Sciences4.785 of 5 stars$95.44-0.6%$98.39+3.1%+42.5%$118.97B$27.12B1,060.6718,000Earnings ReportAnalyst ForecastInsider TradeShort Interest ↓Analyst RevisionALNYAlnylam Pharmaceuticals4.547 of 5 stars$272.47-1.3%$298.61+9.6%+56.2%$35.14B$2.09B-103.982,100Earnings ReportAnalyst ForecastShort Interest ↓News CoverageBIIBBiogen4.7968 of 5 stars$141.49+0.1%$228.80+61.7%-37.8%$20.62B$9.61B12.797,570Earnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionNews CoverageUTHRUnited Therapeutics4.4775 of 5 stars$347.78+0.0%$382.08+9.9%+72.8%$15.53B$2.76B15.281,168Insider TradeAnalyst RevisionINCYIncyte4.561 of 5 stars$69.30-6.5%$75.71+9.2%+21.6%$13.35B$3.70B495.032,524Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionBMRNBioMarin Pharmaceutical4.7627 of 5 stars$63.67-0.4%$94.20+48.0%-24.6%$12.13B$2.42B38.133,401Analyst UpgradePositive NewsNBIXNeurocrine Biosciences4.8915 of 5 stars$116.90-4.7%$168.35+44.0%-12.7%$11.84B$2.36B35.531,400Analyst ForecastInsider TradeShort Interest ↓EXELExelixis4.8344 of 5 stars$33.92+1.3%$36.06+6.3%+71.7%$9.71B$1.83B21.791,310Earnings ReportAnalyst DowngradeShort Interest ↓Analyst Revision Related Companies and Tools Related Companies Amgen Alternatives Vertex Pharmaceuticals Alternatives Gilead Sciences Alternatives Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:REGN) was last updated on 2/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredElon’s Chosen OnesMillions of Federal employees just got put on notice... In a single sweeping move, President Trump just off...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.